Greg Skalicky
President
Expertise:
As President of EVERSANA, Greg is responsible for accelerating the company’s growth and ensuring the success of all client commercialization efforts. With more than 25 years of executive leadership, Greg understands all facets of the pharmaceutical industry, spanning clinical operations to commercial success. Greg’s previous roles include Chief Enterprise Business Officer and Executive Vice President and General Manager at a global bio-pharmaceutical solutions organization, where he successfully managed business units and teams of several thousand employees. Skalicky holds a Bachelor of Science in Biology from Temple University and a Master of Business Administration from Villanova University. He is an active member across several industry panels and consortiums.
Articles by Greg Skalicky
The Promise of Direct-to-Patient – What’s Really Needed for Patient Access
In today’s healthcare landscape, patients are no longer passive recipients of care. They are empowered, tech-savvy stakeholders who demand efficiency and transparency. Yet, despite advancements in consumer innovation, the healthcare system often leaves them frustrated with delays and outdated workflows. Imagine a world where patients can swiftly access the right specialists, understand complex therapies, and navigate insurance with ease. This is the promise of the Direct-to-Patient (DTP) model. By integrating technology and patient-centric strategies, DTP accelerates access to care, enhances affordability, and fosters a direct relationship between pharmaceutical brands and patients. How Can a Direct-to-Patient Model Elevate the Patient Experience and Improve Clinical Outcomes? Empowering Patients with Direct Access: Direct-to-patient […]
The Promise of a Direct-to-Patient Model – Breaking Down What’s Really Needed for Better Patient Access
In today’s healthcare landscape, patients are no longer passive recipients of care. They are empowered, tech-savvy stakeholders who demand efficiency and transparency. Yet, despite advancements in consumer innovation, the healthcare system often leaves them frustrated with delays and outdated workflows. Imagine a world where patients can swiftly access the right specialists, understand complex therapies, and navigate insurance with ease. This is the promise of the Direct-to-Patient (DTP) model. By integrating technology and patient-centric strategies, DTP accelerates access to care, enhances affordability, and fosters a direct relationship between pharmaceutical brands and patients. How Can a Direct-to-Patient Model Elevate the Patient Experience and Improve Clinical Outcomes? Empowering Patients with Direct Access: Direct-to-patient […]
The Future of Global Commercialization: Unified, Data-Driven and Patient-Centric
Are you interested in the rapidly evolving pharmaceutical landscape? Do you want to understand the paradigm shift in global commercialization strategies? If so, we have just the resource for you! Download our latest article titled “The Future of Global Commercialization: Unified, Data-Driven and Patient-Centric”. This comprehensive guide provides insights into: The need for a unified, data-driven, and patient-centric approach in global commercialization. The shift from a vendor approach to a partner approach in the pharmaceutical landscape. The importance of leveraging data and technology in commercialization. The emerging trend of patient-centric commercialization strategies. Future trends and strategies in global commercialization. This is a must-read for anyone looking to navigate the complexities […]
Understanding IDNs and What They Mean to the Pharmaceutical Industry–Q&A with Greg Skalicky
Integrated Delivery Networks have impacted everything from drug launches to sales approaches. Integrated Delivery Networks have changed the healthcare landscape over the past decade. Greg Skalicky, President at EVERSANA, spoke with Pharmaceutical Executive about the ways that commercialization teams are working with these networks to bring drugs to markets. Pharmaceutical Executive: How are IDNs being utilized by the pharmaceutical industry? Greg Skalicky: Integrated Delivery Networks, or IDNs, have risen in popularity across the healthcare landscape in recent years. According to data, 70% of all physicians in the US are employed by an IDN – meaning a hospital, a system or other corporate entity. This wasn’t the case a decade ago, […]
Optimizing Product Commercialization in Today’s IDN Environment
The healthcare landscape is undergoing a significant transformation with the rise of Integrated Delivery Networks (IDNs), now employing nearly 70% of U.S. physicians. As IDNs become more prevalent, they bring numerous advantages, such as enhanced physician collaboration across specialties, increased operational efficiencies and improved patient care outcomes. IDNs not only centralize their purchasing efforts but also develop and control their own drug formularies. Consequently, the traditional methods of launching new therapies, such as relying on field teams and media advertising, are no longer sufficient. Today’s strategies must be multi-faceted, addressing the opportunities and challenges presented by the IDN model. Brand teams now face a complex decision-making process involving multiple stakeholders […]
Bending the “Commercialization Curve” in Large Pharma
If the last few years have taught us anything, it’s that it’s more important than ever to embrace change and new ways to bring therapies to patients. This is especially the case when considering commercialization and globalization in the life sciences and pharmaceutical industries. Although many would agree that this adaptation is important, we haven’t seen much change in the last 30 years in the way larger companies are bringing drugs to market. Failure to adapt and embrace new ways of doing things can cause significant challenges for the industry, creating downstream impacts across healthcare, the largest of which is on patients. Despite these pressures, and with the […]
Overcome In-Licensing Barriers to Increase Throughput of Assets
In-licensing is an important growth channel for pharmaceutical companies as they continue to seek more catalysts for growth. In-licensing is used to expand or consolidate a company’s position in a therapy area but can oftentimes be limited by internal restraints. Common Barriers to In-Licensing: Capacity and Capability Constraints Many times, companies are limited in in-licensing more clinically and commercially viable assets due to commercial capacity and capability constraints. In fact, observations from recent due diligence efforts indicate companies eliminate at least 20-30% of potentially viable assets due to not having enough resources to commercialize the asset or not having the unique capabilities necessary to commercialize based on asset or market […]
Reinventing Launch: The Gold Standard Of Drug Commercialization
In a world that is rapidly changing, we must evolve beyond traditional strategies to create true impact for patients. EVERSANA’s complete end-to-end commercialization model enables manufacturers to bring their drug to market at a fraction of the cost of “going it alone” or partnering with another pharmaceutical company.